Press Release
1.7.21

TOPADUR submits an Orphan Drug Designation application for TOP-N53

Zurich-Schlieren, Switzerland, July 1st, 2021. TOPADUR Pharma AG, a biopharmaceutical start-up company today is pleased to announce the submission of an application to the European Medicines Agency (EMA) to receive Orphan Drug Designation (ODD) status for its lead product TOP-N53 to treat digital ulcers in patients with systemic sclerosis.

“The submission of our ODD represents a major milestone for the Company and it brings significant benefits to the development process of TOP-N53,” said Reto Naef, Chairman of the Board of Directors and CEO at TOPADUR Pharma AG. “We believe that TOP-N53 has significant potential to provide a valuable treatment option for digital ulcers in patients afflicted by systemic sclerosis, a disabling condition.”

Download DocumentDokument herunterladen
27.10.20
News

Scientific Publication in Chimia

TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds.

Read more
10.9.20
Press Release

TOPADUR starts clinical development of a new wound healing drug

TOPADUR Pharma AG announces dosing of first healthy subjects in Phase 1 clinical trial of TOP-N53.

Read more
6.7.21
Press Release

TOPADUR Pharma AG announces completion of TOP-N53 First-in-Man Study

TOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.

Read more